pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Hibsago]]>

Read source
pharmexec.com /1 week ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Pimjetmi]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Onswik]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Voceryq]]>

Read source
pharmexec.com /5 days ago

<![CDATA[FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated wit...

Read source
pharmexec.com /5 days ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Three New Therapies]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>

Read source
natlawreview.com /1 month ago

FDA Opens Applications for New Pilot to Shorten Drug Approval Times: What Sponsors Need to Know

Earlier this month, FDA opened applications for a new Expedited Investigational New Drug (IND) Pilot Program (the “Program”), an initiative launched under HHS Operation TrialBlazer...

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tecentriq]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Your Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warning]]>

Read source
pharmexec.com /1 week ago

<![CDATA[FDA Approves asundexian for Secondary Stroke Risk Reduction ]]>

Read source
pharmexec.com /1 week ago

<![CDATA[FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell Tumor]]>

Read source
biopharmadive.com /1 month ago

FDA starts review of Roche’s multiple sclerosis pill

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab]]>

Read source
pharmexec.com /4 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro]]>

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Welireg Plus Lenvima for Previously Treated Adult Patients With ccRCC]]>

Read source
pharmexec.com /4 weeks ago

<![CDATA[FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[FDA Grants Accelerated Approval to Rybrevant Faspro in Head and Neck Cancer]]>

Read source
pharmexec.com /4 days ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly]]>

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.